Drug interactions
Liposomal doxorubicin + Lorlatinib
Severity: Minor
Liposomal doxorubicin and Lorlatinib: minor interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
Lorlatinib induces CYP3A4 and could theoretically reduce doxorubicin exposure. Because CYP3A4 contributes little to doxorubicin elimination, a meaningful effect is unlikely and has not been demonstrated.
What this interaction means in plain words
Liposomal doxorubicin and Lorlatinib have a small, usually unimportant interaction. Most people can take both; the pharmacist may still mention it so that any unexpected effect is recognised.
Liposomal doxorubicin belongs to Oncology; Lorlatinib belongs to Oncology.
Why it happens
Lorlatinib induces CYP3A4 (and possibly P-gp), a minor pathway for doxorubicin disposition.
What to do
No dose adjustment is required; monitor treatment response and standard toxicity parameters.
What to ask your pharmacist
- Is there anything I should notice while taking both?
- Do I need to tell my doctor at the next visit?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Liposomal doxorubicin and Lorlatinib, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 7 days on the web. No card needed.
Other interactions of Liposomal doxorubicin
- Dengue vaccine + Liposomal doxorubicin Contraindicated
- Belatacept + Liposomal doxorubicin Major
- Cyclosporine + Liposomal doxorubicin Major
- Dronedarone + Liposomal doxorubicin Major
- Elvitegravir / cobicistat / emtricitabine / tenofovir df + Liposomal doxorubicin Major
- Fingolimod + Liposomal doxorubicin Major
Other interactions of Lorlatinib
- Amobarbital + Lorlatinib Contraindicated
- Apalutamide + Lorlatinib Contraindicated
- Butabarbital + Lorlatinib Contraindicated
- Carbamazepine + Lorlatinib Contraindicated
- Enzalutamide + Lorlatinib Contraindicated
- Fosphenytoin + Lorlatinib Contraindicated
Frequently asked questions
Can I take Liposomal doxorubicin with Lorlatinib?
MediHelp rates the interaction as minor. Liposomal doxorubicin and Lorlatinib have a small, usually unimportant interaction. Most people can take both; the pharmacist may still mention it so that any unexpected effect is recognised. Lorlatinib induces CYP3A4 and could theoretically reduce doxorubicin exposure. Because CYP3A4 contributes little to doxorubicin elimination, a meaningful effect is unlikely and has not been demonstrated.
How serious is the interaction between Liposomal doxorubicin and Lorlatinib?
MediHelp rates it minor, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: No dose adjustment is required; monitor treatment response and standard toxicity parameters.
What other medicines interact with Liposomal doxorubicin?
MediHelp also lists interactions of Liposomal doxorubicin with, for example, Dengue vaccine, Belatacept, Cyclosporine. The full list is on the Liposomal doxorubicin page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
